About Benralizumab
            
            Class: | Monoclonal antibody (anti-IL-5 receptor alpha)  
Use: | Treatment of severe asthma with eosinophilic phenotype, and for the treatment of chronic rhinosinusitis with nasal polyps in adults  
Adult dose: | 30 mg administered subcutaneously every 4 weeks for the first 3 doses, then every 8 weeks thereafter  
Pediatric dose: | Not approved for use in pediatric patients under 18 years of age  
Side effects: | Headache, injection site reactions, pharyngitis, fever, and fatigue  
Contraindicat
         
        
            
                
                
                    
                        Drug Class
                    
                    Monoclonal antibody (anti-IL-5 receptor alpha)
                 
                
                
                    
                        Uses & Indications
                    
                    Treatment of severe asthma with eosinophilic phenotype, and for the treatment of chronic rhinosinusitis with nasal polyps in adults
                 
                
                
                    
                        Storage Requirements
                    
                    Store in the refrigerator at 2°C to 8°C (36°F to 46°F); do not freeze; can be kept at room temperature (up to 25°C or 77°F) for a maximum of 14 days
                 
                
                
                    
                        Manufacturer & Packaging
                    
                    
                        Manufacturer: AstraZeneca AB, SWEDEN
                    
                    
                    Package Size
                    1 Pre-Filled Syringe
                    
                    
                    Price & Supplier
                    
                        Price in UAE: AED 13308.00
                    
                    
                 
             
            
                
                
                    
                        Dosage Information
                    
                    
                        Adult Dose
                    
                    
                        30 mg administered subcutaneously every 4 weeks for the first 3 doses, then every 8 weeks thereafter
                    
                    
                        Pediatric Dose
                    
                    
                        Not approved for use in pediatric patients under 18 years of age
                    
                 
                
                
                    
                        Side Effects
                    
                    Headache, injection site reactions, pharyngitis, fever, and fatigue
                 
             
         
        
        
            
                Contraindications & Precautions
            
            Hypersensitivity to benralizumab or any component of the formulation; caution in patients with a history of hypersensitivity reactions
         
        
        
            
                Important Warnings
            
            Risk of anaphylaxis; monitor for hypersensitivity reactions; not for the treatment of acute asthma symptoms or exacerbations; may cause reduction in eosinophil counts leading to potential infections
         
        
        
        
        
        
        
        
            
                Related Medicines in Same Category
            
            
                See also: Other Monoclonal antibody (anti-IL-5 receptor alpha) medicines available in UAE pharmacies
            
            
            
                Benralizumab (FASENRA)
            
            
         
        
        
        
            
                Medical Disclaimer
            
            
                This information is for educational purposes only and should not replace professional medical advice. 
                Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication. 
                The information presented here is specific to medicines available in UAE pharmacies and is regularly updated 
                to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.